Plain English Summary
Background and study aims
An osteochondral lesion of the talus (OLT) is a common condition involving injuries to the talus (the bottom bone of the ankle joint) that involve both the bone and the overlying cartilage. These injuries are usually caused by a single traumatic injury to the ankle joint, such as a sprain, and symptoms include pain, swelling and instability of the joint. This can leads to problems putting weight on the ankle, causing problems with mobility. Treatment of OLT may involve non-surgical techniques such as wearing an ankle brace or surgery to restore the normal shape and movement of the talus. For patients with Hepple Phase I-III OLT (where the fracture has not separated the bone fragments) surgery is usually performed using arthroscopic techniques (which use a camera and small instruments to view and work within the joint through small incisions). This is generally effective however some patients still suffer from long-term pain after surgery. Shock wave therapy (SWT) is a type of physical therapy which uses sound waves to stimulate healing. The aim of this study is to find out whether treatment with SWT can help reduce pain and improve healing after arthroscopic surgery for OLT.
Who can participate?
Adults with OLT who are admitted to one of the four participating hospitals.
What does the study involve?
Participants who have received standard arthroscopic surgery are randomly allocated to one of two groups 10-12 weeks after surgery. Those in the first group have shock wave therapy. This involves applying low levels of sound waves to the affected area every other day for five treatments and gradually increasing the amount of energy used. Those in the second group are treated using equipment similar with the shock wave treatment in appearance but that does not produce any sound waves (dummy treatment). At the start of the study and then after six weeks, three, six and twelve months, participants in both groups are asked to rate their pain levels and ankle function. In addition, the ankle joint is scanned to evaluate healing three and twelve months after surgery.
What are the possible benefits and risks of participating?
Participants benefit from receiving high level OLT assessments. As the effectiveness of the combined treatment is not yet proven, the opportunity to receive this shock wave treatment cannot be called a benefit. There is a small risk of skin irritation or redness from the shock treatment and a very small risk of injury to the nerves or bones from having the treatment.
Where is the study run from?
1. Southwest Hospital (China)
2. Chinese People’s Armed Police General Hospital (China)
3. Beijing Tongren Hospital (China)
4. Huashan Hospital (China)
When is the study starting and how long is it expected to run for?
December 2016 to July 2019
Who is funding the study?
Southwest Hospital (China)
Who is the main contact?
Professor Xiaojun Duan
arthro@126.com
Trial website
Contact information
Type
Scientific
Primary contact
Mr Xiaojun Duan
ORCID ID
http://orcid.org/0000-0001-7644-2452
Contact details
Centre for Joint Surgery
Southwest Hospital
No. 30 Gaotanyan Street
Shapingba District
Chongqing
400038
China
+86 23 68765290
arthro@126.com
Additional identifiers
EudraCT number
ClinicalTrials.gov number
Protocol/serial number
V1.3
Study information
Scientific title
Arthroscopicsurgery combined with postoperative shock wave therapy for treating osteochondral lesions of the talus: A prospective, multicentre, randomised, double-blind clinical study
Acronym
Study hypothesis
The aim of this study is to estimate the safety and feasibility of arthroscopic surgery combined with postoperative shock wave therapy for treating osteochondral lesions of the talus.
Ethics approval
Ethics Board: Medical Ethics Committee of Southwest Hospital, China, 24/01/2017, ref: [2017] No. 8 Keyan
Study design
Prospective double-blind multi-centre randomised controlled trial
Primary study design
Interventional
Secondary study design
Randomised controlled trial
Trial setting
Hospitals
Trial type
Treatment
Patient information sheet
Not available in web format, please use the contact details below to request a patient information sheet
Condition
Osteochondral Lesions of the Talus, Hepple Phase Ⅰ-Ⅲ
Intervention
Patients who are diagnosed as Osteochondral Lesions of the Talus (OLT) at the outpatient department will be admitted to the hospital. The OLT will be treated with conventional arthroscopic surgery and micro-fracture. 10-12 weeks after operation, if no complications are found, the patients will be selected as the participants of the study after obtaining their consents. The participants will be randomly allocated to one of two groups.
Experimental group: Participants will be treated with shock wave treatment at 12 weeks post-operatively. The energy level of the shock wave treatment should be adjusted according to the pain sensitivity of each participant, starting from low-level and gradually increasing to the required level; the energy density will be set at 0.18-0.25mJ / mm2. 2-3 treatment points will be chosen in each treatment; each point will receive shock wave for 1000 times, totaling 2000-3000 times. The treatment will be given on every other day. 1 course consists of 5 treatments, and the participants in the experimental group will be treated for 1 course.
Control group: Participants will be treated by equipment similar with the shock wave treatment in appearance but has no energy output.
Participants are followed up by the visual analogue scale (VAS) and AOFAS scoring system at baseline, 6 weeks, 3, 6 and 12 months; as well as MRI imaging at pre-operatively, and 3, 12 months post-operatively.
Intervention type
Mixed
Phase
Drug names
Primary outcome measures
1. Function of the ankle joint is measured using the AOFAS scoring system at baseline, 6 weeks, 3, 6 and 12 months
2. Pain in the ankle joint is measured using the visual analogue scale at baseline, 6 weeks, 3, 6 and 12 months
3. Repair of the OLT is assessed using MRI scanning pre-operatively, and 3 and 12 months post-operatively
Secondary outcome measures
1. Patient death rate is assessed by reviewing medical notes at 12 months
2. Serious complications that require other treatment are assessed by participant interviews at 12 months
Overall trial start date
05/12/2016
Overall trial end date
31/07/2019
Reason abandoned
Eligibility
Participant inclusion criteria
1. Age 18 years or more and less than 80 years (including 80 years)
2. The disease lasts for more than 6 months; symptoms still remain after drug treatment
3. MRI suggests the diagnosis of Hepple Phase-Ⅲ Osteochondral Lesions of the Talus
4. The AOFAS score is lower than 75 after 10-12 weeks of ankle arthroscopy
5. Patients who sign the informed consent, agree to participant in the study and cooperate during the follow-up
Participant type
Patient
Age group
Adult
Gender
Both
Target number of participants
32
Participant exclusion criteria
1. Age less than 18 years or more than 80 years
2. MRI suggests Hepple Phase Ⅳ Osteochondral Lesions of the Talus associated with huge bone cyst
3. X-ray suggests malalignment of the lower limb or ankle joint (varus, valgus> 10 degrees)
4. Surgery history and shock wave treatment history of the ankle joint
5. Ankle OA, gout, local infection, coagulation abnormalities
6. Ankle ligamentous injury, or associated with other lesions that need surgical intervention
7. Pregnant women, deaf patients, or patients with mental disorders, etc., are excluded to ensure the accuracy of the follow-up
8. AOFAS scores of 10-12 weeks after ankle arthroscopy more than or equal to 75
Recruitment start date
01/02/2017
Recruitment end date
31/07/2018
Locations
Countries of recruitment
China
Trial participating centre
Southwest Hospital
No. 30 Gaotanyan Street
Shapingba District
Chongqing
400038
China
Trial participating centre
Chinese People’s Armed Police General Hospital
No. 69, Yongding Road
Haidian District
Beijing
100039
China
Trial participating centre
Beijing Tongren Hospital
No. 1 Dongjiaominxiang
Dongcheng District
Beijing
100730
China
Trial participating centre
Huashan Hospital
No. 12 Urumqi Middle Road
Shanghai
200040
China
Sponsor information
Organisation
Southwest Hospital
Sponsor details
No. 30 Gaotanyan Street
Shapingba District
Chongqing
400038
China
+86 23 68765290
jointsurgery@163.com
Sponsor type
Hospital/treatment centre
Website
Funders
Funder type
Hospital/treatment centre
Funder name
Southwest Hospital
Alternative name(s)
Funding Body Type
Funding Body Subtype
Location
Results and Publications
Publication and dissemination plan
The study will be reported at the 22nd International Society for Medical Shockwave Treatment (ISMSC) Congress held in 2019. Planned publication in a high-impact peer reviewed journal in 2020.
Intention to publish date
31/12/2020
Participant level data
To be made available at a later date
Results - basic reporting
Publication summary